BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis. PLoS One 2017;12:e0169691. [PMID: 28072858 DOI: 10.1371/journal.pone.0169691] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Poly TN, Lin M, Syed-abdul S, Huang C, Yang H, Li Y(. Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal. Cancers 2022;14:3052. [DOI: 10.3390/cancers14133052] [Reference Citation Analysis]
2 Choi HG, Lee HK, Kang HS, Lim H, Kim J, Kim JH, Kim NY, Cho S, Nam ES, Min K, Kwon MJ. Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort. Pharmaceuticals 2022;15:517. [DOI: 10.3390/ph15050517] [Reference Citation Analysis]
3 Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol 2022;117:559-87. [PMID: 35354777 DOI: 10.14309/ajg.0000000000001680] [Cited by in Crossref: 9] [Article Influence: 9.0] [Reference Citation Analysis]
4 Yao H, Wang L, Li H, Xu S, Bai Z, Wu Y, Chen H, Goyal H, Qi X. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2021;:1-10. [PMID: 34806503 DOI: 10.1080/17512433.2022.2008909] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Alkhayyat M, Kumar P, Sanaka KO, Thota PN. Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma. Therap Adv Gastroenterol 2021;14:17562848211033730. [PMID: 34434254 DOI: 10.1177/17562848211033730] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hamade N, Weng G, Desai M, Chandrasekar VT, Dasari C, Kennedy K, Sharma P. Significant decline in the prevalence of Barrett's esophagus among patients with gastroesophageal reflux disease. Dis Esophagus 2021;34:doaa131. [PMID: 33458760 DOI: 10.1093/dote/doaa131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen Y, Sun C, Wu Y, Chen X, Kailas S, Karadsheh Z, Li G, Guo Z, Yang H, Hu L, Zhou Q. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol 2021;147:2681-91. [PMID: 33575855 DOI: 10.1007/s00432-021-03544-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Friedman AJ, Elseth AJ, Brockmeyer JR. Proton Pump Inhibitors, Associated Complications, and Alternative Therapies: A Shifting Risk Benefit Ratio. Am Surg 2021;:3134821991988. [PMID: 33560890 DOI: 10.1177/0003134821991988] [Reference Citation Analysis]
10 Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA 2020;324:2536-47. [PMID: 33351048 DOI: 10.1001/jama.2020.21360] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
11 Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. [DOI: 10.1136/bmj.m3786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Moayyedi P, El-Serag HB. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:117-30. [PMID: 33213791 DOI: 10.1016/j.giec.2020.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dunn CP, Henning JC, Sterris JA, Won P, Houghton C, Bildzukewicz NA, Lipham JC. Regression of Barrett’s esophagus after magnetic sphincter augmentation: intermediate-term results. Surg Endosc 2021;35:5804-9. [DOI: 10.1007/s00464-020-08074-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Smith LP, Yamato JA, Galipeau PC, Paulson TG, Li X, Sanchez CA, Reid BJ, Kuhner MK. Within-patient phylogenetic reconstruction reveals early events in Barrett's Esophagus. Evol Appl 2021;14:399-415. [PMID: 33664784 DOI: 10.1111/eva.13125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Snider EJ, Kaz AM, Inadomi JM, Grady WM. Chemoprevention of esophageal adenocarcinoma. Gastroenterol Rep (Oxf) 2020;8:253-60. [PMID: 32843972 DOI: 10.1093/gastro/goaa040] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yin CY, Zhang SS, Zhong JT, Zhou SH. Pepsin and Laryngeal and Hypopharyngeal Carcinomas. Clin Exp Otorhinolaryngol 2021;14:159-68. [PMID: 32734742 DOI: 10.21053/ceo.2020.00465] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Zhou J, Shrestha P, Qiu Z, Harman DG, Teoh WC, Al-Sohaily S, Liem H, Turner I, Ho V. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma. J Clin Med. 2020;9. [PMID: 32650561 DOI: 10.3390/jcm9072162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 McCormick CA, Samuels TL, Battle MA, Frolkis T, Blumin JH, Bock JM, Wells C, Yan K, Altman KW, Johnston N. H+/K+ATPase Expression in the Larynx of Laryngopharyngeal Reflux and Laryngeal Cancer Patients. Laryngoscope 2021;131:130-5. [PMID: 32250454 DOI: 10.1002/lary.28643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
21 Samuels TL, Zimmermann MT, Zeighami A, Demos W, Southwood JE, Blumin JH, Bock JM, Johnston N. RNA Sequencing Reveals Cancer-Associated Changes in Laryngeal Cells Exposed to Non-Acid Pepsin. Laryngoscope 2021;131:121-9. [PMID: 32202667 DOI: 10.1002/lary.28636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Zhang T, Wang Q, Ma WY, Wang K, Chang X, Johnson ML, Bai R, Bode AM, Foster NR, Falk GW, Limburg PJ, Iyer PG, Dong Z. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. EBioMedicine 2019;49:145-56. [PMID: 31707149 DOI: 10.1016/j.ebiom.2019.10.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Straub D, Oude Elferink RPJ, Jansen PLM, Bergman JJGHM, Parikh K, Krishnadath KK. Glyco-conjugated bile acids drive the initial metaplastic gland formation from multi-layered glands through crypt-fission in a murine model. PLoS One 2019;14:e0220050. [PMID: 31348796 DOI: 10.1371/journal.pone.0220050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Doukas SG, Cardoso B, Tower JI, Vageli DP, Sasaki CT. Biliary tumorigenic effect on hypopharyngeal cells is significantly enhanced by pH reduction. Cancer Med 2019;8:4417-27. [PMID: 31173474 DOI: 10.1002/cam4.2194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
25 Wu PC, Chen YH, Wu FZ, Lin KH, Hsu CL, Chen CS, Chen YH, Lin PH, Mar GY, Yu HC. Risk factors for Barrett's esophagus in young adults who underwent upper gastrointestinal endoscopy in a health examination center. Therap Adv Gastroenterol 2019;12:1756284819853115. [PMID: 31210784 DOI: 10.1177/1756284819853115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Chwiesko A, Kowal-Bielecka O, Sierakowski S. Perspectives on the interlinked nature of systemic sclerosis and reflux disease. Expert Rev Gastroenterol Hepatol. 2019;13:213-227. [PMID: 30791766 DOI: 10.1080/17474124.2019.1561274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am 2019;103:1-14. [PMID: 30466666 DOI: 10.1016/j.mcna.2018.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
28 Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks C, Attwood S, Harrison R, Barr H, Moayyedi P;  AspECT Trial Team. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400-408. [PMID: 30057104 DOI: 10.1016/s0140-6736(18)31388-6] [Cited by in Crossref: 100] [Cited by in F6Publishing: 40] [Article Influence: 25.0] [Reference Citation Analysis]
29 Tan MC, El-serag HB, Yu X, Thrift AP. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther 2018;48:469-77. [DOI: 10.1111/apt.14895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
30 MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract 2018;7:41-52. [PMID: 29892570 DOI: 10.2147/IPRP.S142932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Targownik L. Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? American Journal of Gastroenterology 2018;113:519-28. [DOI: 10.1038/ajg.2018.29] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
32 Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics 2018;16:33-49. [PMID: 29474889 DOI: 10.1016/j.gpb.2017.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018;16:33-49. [PMID: 29474889 DOI: 10.1016/j.gpb.2017.06.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
34 Coleman HG, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:390-405. [PMID: 28780073 DOI: 10.1053/j.gastro.2017.07.046] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 36.6] [Reference Citation Analysis]